What is HC Wainwright’s Estimate for Evotec Q1 Earnings?

Evotec SE (NASDAQ:EVO) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Evotec in a research report issued on Thursday, November 7th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Evotec’s Q2 2025 earnings at $0.01 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at $0.02 EPS.

Several other brokerages have also weighed in on EVO. Morgan Stanley lowered shares of Evotec from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $15.00 to $6.00 in a research report on Monday, July 29th. Jefferies Financial Group cut Evotec from a “buy” rating to a “hold” rating and lowered their price target for the stock from $8.70 to $3.80 in a report on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft cut Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to MarketBeat, Evotec has an average rating of “Hold” and a consensus target price of $5.93.

Evotec Stock Performance

Shares of EVO opened at $4.13 on Friday. The company has a current ratio of 1.83, a quick ratio of 1.73 and a debt-to-equity ratio of 0.42. Evotec has a 52-week low of $2.85 and a 52-week high of $12.00. The company has a 50-day simple moving average of $3.51 and a 200-day simple moving average of $4.21.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Novo Holdings A S purchased a new stake in Evotec during the 2nd quarter worth about $71,183,000. Cetera Advisors LLC acquired a new stake in shares of Evotec during the 1st quarter worth about $188,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Evotec during the second quarter worth about $87,000. DCF Advisers LLC raised its position in shares of Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after buying an additional 67,156 shares during the last quarter. Finally, Mediolanum International Funds Ltd purchased a new position in shares of Evotec during the third quarter valued at approximately $512,000. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.